Background: The pathogenesis of inflammatory bowel disease (IBD) is complex and involves the contribution of genetic and environmental factors. Many patients with very early onset IBD are difficult to treat. The current antibiotic medication that targets gram-negative and anaerobic bacteria provides only moderate efficacy in subsets of patients with IBD. Methods: We report a case series of 5 children with a mean age of 1.6 years (range 6 months to 2.7 years) during IBD onset, who were previously refractory to standard treatments and who received oral vancomycin with or without gentamicin. Results: Four out of 5 children demonstrated substantial therapeutic effect, and the effect was sustained in 3 children over a follow-up period of 12-33 months. Conclusion: Our findings are consistent with model systems and suggest that randomized trials are required to establish whether a change in therapeutic paradigm, that is, targeting gram-positive bacteria with nonabsorbable antibiotics, may have therapeutic benefits.

Keywords:
Crohn disease, Ulcerative colitis, Primary sclerosing cholangitis, Antibiotics
1.
Peloquin JM, Goel G, Villablanca EJ, Xavier RJ: Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol 2016;34:31-64.
2.
Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al: The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014;147:990-1007.e3.
3.
Ledder O, Catto-Smith AG, Oliver MR, Alex G, Cameron DJ, Hardikar W: Clinical patterns and outcome of early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;59:562-564.
4.
Cox KL, Cox KM: Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:580-583.
5.
Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, et al: Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013;33:397-406.
6.
Elliott TR, Hudspith BN, Wu G, Cooley M, Parkes G, Quiñones B, et al: Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2326-2338.
7.
Kammermeier J, Drury S, James CT, Dziubak R, Ocaka L, Elawad M, et al: Targeted gene panel sequencing in children with very early onset inflammatory bowel disease - evaluation and prospective analysis. J Med Genet 2014;51:748-755.
8.
Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380-1384.
9.
Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL: Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61-67.
10.
Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al: Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013;37:604-612.
11.
Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-129.
12.
Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al: Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003;52:237-242.
13.
Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL: Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. Pharmacotherapy 2015;35:119-126.
14.
Antoon JW, Hall M, Metropulos D, Steiner MJ, Jhaveri R, Lohr JA: A prospective pilot study on the systemic absorption of oral vancomycin in children with colitis. J Pediatr Pharmacol Ther 2016;21:426-431.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.